Clinical Trials

The primary purpose of this study is to assess the safety of extended treatment and retreatment with efgartigimod PH20 SC in patients with Pemphigus Vulgaris (PV) or Pemphigus Foliaceus (PF).

The primary purpose of this study is to demonstrate the effectiveness of efgartigimod PH20 SC compared to placebo in the treatment of patients with Pemphigus Vulgaris (PV).  

The purpose of this study is to obtain serum from patients with certain rare immunobullous diseases (e.g., paraneoplastic pemphigus, laminin-332 pemphigoid) to replenish a source of positive control for our clinical testing (e.g., Mayo test codes PNPAB, RSBV).  

• To verify the performance characteristics of anti-Paraneoplastic Pemphigus (PNP) serum and validate its use as a positive control in PNP test.  

• Serum from patients with PNP will be used for a positive control for the PNP test upon successful validation. 

Background:  

For various rare immunobullous diseases, detection of a circulating autoantibody is necessary for accurate diagnosis. As a CLIA requirement, every clinical test run requires positive ...

The purpose of this study is to evaluate the effectiveness and safety of oral PRN1008 in moderate to severe pemphigus.